pmc logo image
Logo of westjmedJournal URL: http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=183&action=archive
Journal List > West J Med > v.156(6); Jun 1992

Formats:
West J Med. 1992 June; 156(6): 639–646.
PMCID: PMC1003353
Copyright notice
Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update.
J. E. Merrill, M. C. Graves, and D. G. Mulder
Department of Neurology, UCLA School of Medicine 90024.
Abstract
Autoimmunity in the central and peripheral nervous system can manifest as the result of cellular or humoral immune responses to autoantigens. There is evidence that multiple sclerosis is a cell-mediated autoimmune disease of the central nervous system in which both myelin and the cell that produces the myelin are destroyed. Diseases such as acute inflammatory demyelinating polyneuropathy (also called Guillain-Barré syndrome) and myasthenia gravis are considered antibody-mediated diseases of the peripheral nervous system and neuromuscular junctions, respectively. We review these diseases and explore mechanisms of immune-mediated destruction of these nervous system components. We specifically focus on one effective therapy aimed at countering the immune attack, that of thymectomy in patients with myasthenia gravis.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.9M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 639
639
icon of scanned page 640
640
icon of scanned page 641
641
icon of scanned page 642
642
icon of scanned page 643
643
icon of scanned page 644
644
icon of scanned page 645
645
icon of scanned page 646
646
 
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • McFarlin DE, McFarland HF. Multiple sclerosis (first of two parts). N Engl J Med. 1982 Nov 4;307(19):1183–1188. [PubMed]
  • Gebarski SS, Gabrielsen TO, Gilman S, Knake JE, Latack JT, Aisen AM. The initial diagnosis of multiple sclerosis: clinical impact of magnetic resonance imaging. Ann Neurol. 1985 May;17(5):469–474. [PubMed]
  • Paty DW, McFarlin DE, McDonald WI. Magnetic resonance imaging and laboratory aids in the diagnosis of multiple sclerosis. Ann Neurol. 1991 Jan;29(1):3–5. [PubMed]
  • Oger J, Kastrukoff L, O'Gorman M, Paty DW. Progressive multiple sclerosis: abnormal immune functions in vitro and aberrant correlation with enumeration of lymphocyte subpopulations. J Neuroimmunol. 1986 Jul;12(1):37–48. [PubMed]
  • Calder V, Owen S, Watson C, Feldmann M, Davison A. MS: a localized immune disease of the central nervous system. Immunol Today. 1989 Mar;10(3):99–103. [PubMed]
  • Hafler DA, Weiner HL. MS: a CNS and systemic autoimmune disease. Immunol Today. 1989 Mar;10(3):104–107. [PubMed]
  • Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature. 1988 Aug 4;334(6181):395–402. [PubMed]
  • Brown JH, Jardetzky T, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature. 1988 Apr 28;332(6167):845–850. [PubMed]
  • Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature. 1986 Nov 20;324(6094):258–260. [PubMed]
  • Ando DG, Clayton J, Kono D, Urban JL, Sercarz EE. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol. 1989 Nov;124(1):132–143. [PubMed]
  • Kono DH, Urban JL, Horvath SJ, Ando DG, Saavedra RA, Hood L. Two minor determinants of myelin basic protein induce experimental allergic encephalomyelitis in SJL/J mice. J Exp Med. 1988 Jul 1;168(1):213–227. [PubMed]
  • Clayton JP, Gammon GM, Ando DG, Kono DH, Hood L, Sercarz EE. Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein. J Exp Med. 1989 May 1;169(5):1681–1691. [PubMed]
  • Sayetta RB. Theories of the etiology of multiple sclerosis: a critical review. J Clin Lab Immunol. 1986 Oct;21(2):55–70. [PubMed]
  • Hofman FM, von Hanwehr RI, Dinarello CA, Mizel SB, Hinton D, Merrill JE. Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol. 1986 May 1;136(9):3239–3245. [PubMed]
  • Traugott U, Lebon P. Interferon-gamma and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions. J Neurol Sci. 1988 Apr;84(2-3):257–264. [PubMed]
  • Woodroofe MN, Bellamy AS, Feldmann M, Davison AN, Cuzner ML. Immunocytochemical characterisation of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth. J Neurol Sci. 1986 Jul;74(2-3):135–152. [PubMed]
  • Oldstone MB. Molecular mimicry and autoimmune disease. Cell. 1987 Sep 11;50(6):819–820. [PubMed]
  • Hafler DA, Benjamin DS, Burks J, Weiner HL. Myelin basic protein and proteolipid protein reactivity of brain- and cerebrospinal fluid-derived T cell clones in multiple sclerosis and postinfectious encephalomyelitis. J Immunol. 1987 Jul 1;139(1):68–72. [PubMed]
  • Hafler DA, Duby AD, Lee SJ, Benjamin D, Seidman JG, Weiner HL. Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1988 Apr 1;167(4):1313–1322. [PubMed]
  • Merrill JE, Kagan JM, Schmid I, Strom SR, Quan SG, Chen IS. T cell lines established from multiple sclerosis cerebrospinal fluid T cells using human retroviruses. J Neuroimmunol. 1989 Feb;21(2-3):213–226. [PubMed]
  • Rotteveel FT, Kuenen B, Kokkelink I, Meager A, Lucas CJ. Relative increase of inflammatory CD4+ T cells in the cerebrospinal fluid of multiple sclerosis patients and control individuals. Clin Exp Immunol. 1990 Jan;79(1):15–20. [PubMed]
  • Greenstein JI, McFarland HF, Richert JR. Characterization of antigen-specific T cells in multiple sclerosis twins with elevated proliferative responses to measles virus. J Immunol. 1986 Jul 15;137(2):546–550. [PubMed]
  • Estes ML, Rudick RA, Barnett GH, Ransohoff RM. Stereotactic biopsy of an active multiple sclerosis lesion. Immunocytochemical analysis and neuropathologic correlation with magnetic resonance imaging. Arch Neurol. 1990 Dec;47(12):1299–1303. [PubMed]
  • Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science. 1990 Feb 9;247(4943):718–721. [PubMed]
  • Oksenberg JR, Stuart S, Begovich AB, Bell RB, Erlich HA, Steinman L, Bernard CC. Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients. Nature. 1990 May 24;345(6273):344–346. [PubMed]
  • Seboun E, Robinson MA, Doolittle TH, Ciulla TA, Kindt TJ, Hauser SL. A susceptibility locus for multiple sclerosis is linked to the T cell receptor beta chain complex. Cell. 1989 Jun 30;57(7):1095–1100. [PubMed]
  • Merrill JE, Mohlstrom C, Uittenbogaart C, Kermaniarab V, Ellison GW, Myers LW. Response to and production of interleukin 2 by peripheral blood and cerebrospinal fluid lymphocytes of patients with multiple sclerosis. J Immunol. 1984 Oct;133(4):1931–1937. [PubMed]
  • Selmaj K, Nowak Z, Tchórzewski H. Interleukin-1 and interleukin-2 production by peripheral blood mononuclear cells in multiple sclerosis patients. J Neurol Sci. 1988 May;85(1):67–76. [PubMed]
  • Brajczewska-Fischer W, Iwińska B, Kruszewska J, Korlak J, Członkowska A. Interleukin 1 and 2 production by peripheral blood mononuclear cells in subacute sclerosing panencephalitis and exacerbation of multiple sclerosis. Acta Neurol Scand. 1989 Nov;80(5):390–393. [PubMed]
  • Trotter JL, Clifford DB, McInnis JE, Griffeth RC, Bruns KA, Perlmutter MS, Anderson CB, Collins KG, Banks G, Hicks BC. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol. 1989 Feb;25(2):172–178. [PubMed]
  • Gallo P, Piccinno M, Pagni S, Tavolato B. Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients. Ann Neurol. 1988 Dec;24(6):795–797. [PubMed]
  • Gallo P, Piccinno MG, Pagni S, Argentiero V, Giometto B, Bozza F, Tavolato B. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid. J Neurol Sci. 1989 Aug;92(1):9–15. [PubMed]
  • Trotter JL, van der Veen RC, Clifford DB. Serial studies of serum interleukin-2 in chronic progressive multiple sclerosis patients: occurrence of 'bursts' and effect of cyclosporine. J Neuroimmunol. 1990 Jun;28(1):9–14. [PubMed]
  • Kittur SD, Kittur DS, Soncrant TT, Rapoport SI, Tourtellotte WW, Nagel JE, Adler WH. Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders. Ann Neurol. 1990 Aug;28(2):168–173. [PubMed]
  • Wong GH, Clark-Lewis I, Harris AW, Schrader JW. Effect of cloned interferon-gamma on expression of H-2 and Ia antigens on cell lines of hemopoietic, lymphoid, epithelial, fibroblastic and neuronal origin. Eur J Immunol. 1984 Jan;14(1):52–56. [PubMed]
  • Chung IY, Benveniste EN. Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol. 1990 Apr 15;144(8):2999–3007. [PubMed]
  • Fierz W, Endler B, Reske K, Wekerle H, Fontana A. Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol. 1985 Jun;134(6):3785–3793. [PubMed]
  • Benveniste EN, Sparacio SM, Bethea JR. Tumor necrosis factor-alpha enhances interferon-gamma-mediated class II antigen expression on astrocytes. J Neuroimmunol. 1989 Dec;25(2-3):209–219. [PubMed]
  • Massa PT, Schimpl A, Wecker E, ter Meulen V. Tumor necrosis factor amplifies measles virus-mediated Ia induction on astrocytes. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7242–7245. [PubMed]
  • Traugott U. Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development. J Neuroimmunol. 1987 Oct;16(2):283–302. [PubMed]
  • Hirsch RL, Panitch HS, Johnson KP. Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J Clin Immunol. 1985 Nov;5(6):386–389. [PubMed]
  • Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand. 1988 Oct;78(4):318–323. [PubMed]
  • Olsson T, Zhi WW, Höjeberg B, Kostulas V, Jiang YP, Anderson G, Ekre HP, Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest. 1990 Sep;86(3):981–985. [PubMed]
  • Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987 Apr 18;1(8538):893–895. [PubMed]
  • Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987 Jul;37(7):1097–1102. [PubMed]
  • Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol. 1981 Aug;10(2):149–158. [PubMed]
  • Dore-Duffy P, Donaldson JO, Koff T, Longo M, Perry W. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology. 1986 Dec;36(12):1587–1590. [PubMed]
  • Merrill JE, Gerner RH, Myers LW, Ellison GW. Regulation of natural killer cell cytotoxicity by prostaglandin E in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. Part 1. Association between amount of prostaglandin produced, natural killer, and endogenous interferon. J Neuroimmunol. 1983 Jun;4(3):223–237. [PubMed]
  • Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest. 1982 Nov;47(5):412–426. [PubMed]
  • Hammann KP, Nix W, Dierich MP, Hopf HC. Multiple sclerosis patients show an increased spontaneous activity of their peripheral blood monocytes as measured by chemiluminescence. Acta Neurol Scand. 1983 Sep;68(3):151–156. [PubMed]
  • Hunter MI, Nlemadim BC, Davidson DL. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res. 1985 Dec;10(12):1645–1652. [PubMed]
  • Feldberg W, Gupta KP. Pyrogen fever and prostaglandin-like activity in cerebrospinal fluid. J Physiol. 1973 Jan;228(1):41–53. [PubMed]
  • Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA, Jr, O'Connor JV. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1433–1450. [PubMed]
  • Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature. 1986 Sep 4;323(6083):86–89. [PubMed]
  • Merrill JE, Strom SR, Ellison GW, Myers LW. In vitro study of mediators of inflammation in multiple sclerosis. J Clin Immunol. 1989 Mar;9(2):84–96. [PubMed]
  • Selmaj K, Nowak Z, Tchórzewski H. Multiple sclerosis: effect of myelin basic protein on interleukin 1, interleukin 2 production and interleukin 2 receptor expression in vitro. Clin Exp Immunol. 1988 Jun;72(3):428–433. [PubMed]
  • Franciotta DM, Grimaldi LM, Martino GV, Piccolo G, Bergamaschi R, Citterio A, Melzi d'Eril GV. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol. 1989 Dec;26(6):787–789. [PubMed]
  • Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med. 1989 Aug 1;170(2):607–612. [PubMed]
  • Leist TP, Frei K, Kam-Hansen S, Zinkernagel RM, Fontana A. Tumor necrosis factor alpha in cerebrospinal fluid during bacterial, but not viral, meningitis. Evaluation in murine model infections and in patients. J Exp Med. 1988 May 1;167(5):1743–1748. [PubMed]
  • Nadal D, Leppert D, Frei K, Gallo P, Lamche H, Fontana A. Tumour necrosis factor-alpha in infectious meningitis. Arch Dis Child. 1989 Sep;64(9):1274–1279. [PubMed]
  • Gallo P, Piccinno MG, Krzalic L, Tavolato B. Tumor necrosis factor alpha (TNF alpha) and neurological diseases. Failure in detecting TNF alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours. J Neuroimmunol. 1989 Jun;23(1):41–44. [PubMed]
  • Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 1990 Nov;40(11):1735–1739. [PubMed]
  • Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6348–6352. [PubMed]
  • Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 1989 Jul 10;491(2):394–397. [PubMed]
  • Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E. Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol. 1982 Dec;129(6):2413–2419. [PubMed]
  • Giulian D, Lachman LB. Interleukin-1 stimulation of astroglial proliferation after brain injury. Science. 1985 Apr 26;228(4698):497–499. [PubMed]
  • Lachman LB, Brown DC, Dinarello CA. Growth-promoting effect of recombinant interleukin 1 and tumor necrosis factor for a human astrocytoma cell line. J Immunol. 1987 May 1;138(9):2913–2916. [PubMed]
  • Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol. 1990 Jan 1;144(1):129–135. [PubMed]
  • Merrill JE. Effects of interleukin-1 and tumor necrosis factor-alpha on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro. Dev Neurosci. 1991;13(3):130–137. [PubMed]
  • Merrill JE, Zimmerman RP. Natural and induced cytotoxicity of oligodendrocytes by microglia is inhibitable by TGF beta. Glia. 1991;4(3):327–331. [PubMed]
  • Robbins DS, Shirazi Y, Drysdale BE, Lieberman A, Shin HS, Shin ML. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol. 1987 Oct 15;139(8):2593–2597. [PubMed]
  • Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol. 1988 Apr;23(4):339–346. [PubMed]
  • Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature. 1988 Jul 21;334(6179):260–262. [PubMed]
  • Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol. 1991 May 1;146(9):3012–3017. [PubMed]
  • Ellison GW, Myers LW. Immunosuppressive drugs in multiple sclerosis: pro and con. Neurology. 1980 Jul;30(7 Pt 2):28–32. [PubMed]
  • Myers LW, Fahey JL, Moody DJ, Mickey MR, Frane MV, Ellison GW. Cyclophosphamide 'pulses' in chronic progressive multiple sclerosis. A preliminary clinical trial. Arch Neurol. 1987 Aug;44(8):828–832. [PubMed]
  • Mickey MR, Ellison GW, Fahey JL, Moody DJ, Myers LW. Correlation of clinical and immunologic states in multiple sclerosis. Arch Neurol. 1987 Apr;44(4):371–375. [PubMed]
  • Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature. 1989 Oct 12;341(6242):541–544. [PubMed]
  • Adorini L, Barnaba V, Bona C, Celada F, Lanzavecchia A, Sercarz E, Suciu-Foca N, Wekerle H. New perspectives on immunointervention in autoimmune diseases. Immunol Today. 1990 Nov;11(11):383–386. [PubMed]
  • Hafler DA, Weiner HL. Immunosuppression with monoclonal antibodies in multiple sclerosis. Neurology. 1988 Jul;38(7 Suppl 2):42–47. [PubMed]
  • Knobler RL, Panitch HS, Braheny SL, Sipe JC, Rice GP, Huddlestone JR, Francis GS, Hooper CK, Kamin-Lewis RM, Johnson KP, et al. Systemic alpha-interferon therapy of multiple sclerosis. Neurology. 1984 Oct;34(10):1273–1279. [PubMed]
  • Bender BS, Bennett R, Laughon BE, Greenough WB, 3rd, Gaydos C, Sears SD, Forman MS, Bartlett JG. Is Clostridium difficile endemic in chronic-care facilities? Lancet. 1986 Jul 5;2(8497):11–13. [PubMed]
  • Milanese C, Salmaggi A, la Mantia L, Corridori F, Nespolo A. Intrathecal beta-interferon in multiple sclerosis. Lancet. 1988 Sep 3;2(8610):563–564. [PubMed]
  • Barna BP, Chou SM, Jacobs B, Yen-Lieberman B, Ransohoff RM. Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol. 1989 Jun;23(1):45–53. [PubMed]
  • Lorish TR, Thorsteinsson G, Howard FM., Jr Stiff-man syndrome updated. Mayo Clin Proc. 1989 Jun;64(6):629–636. [PubMed]
  • Roobol TH, Kazzaz BA, Vecht CJ. Segmental rigidity and spinal myoclonus as a paraneoplastic syndrome. J Neurol Neurosurg Psychiatry. 1987 May;50(5):628–631. [PubMed]
  • Diniz MA, Cunha L, Gonçalves F, Oliveira C. Deux cas de syndrome de l'homme raide avec tremblement. Rev Neurol (Paris). 1986;142(12):918–920. [PubMed]
  • Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, Vicari AM. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med. 1988 Apr 21;318(16):1012–1020. [PubMed]
  • Gorin F, Baldwin B, Tait R, Pathak R, Seyal M, Mugnaini E. Stiff-man syndrome: a GABAergic autoimmune disorder with autoantigenic heterogeneity. Ann Neurol. 1990 Nov;28(5):711–714. [PubMed]
  • Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med. 1990 May 31;322(22):1555–1560. [PubMed]
  • Brashear HR, Phillips LH., 2nd Autoantibodies to GABAergic neurons and response to plasmapheresis in stiff-man syndrome. Neurology. 1991 Oct;41(10):1588–1592. [PubMed]
  • Williams DB, Windebank AJ. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin Proc. 1991 Jan;66(1):54–82. [PubMed]
  • Drachman DB, Kuncl RW. Amyotrophic lateral sclerosis: an unconventional autoimmune disease? Ann Neurol. 1989 Aug;26(2):269–274. [PubMed]
  • Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, Alderson K, Adams RN. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988 Jul;24(1):73–78. [PubMed]
  • Pestronk A, Chaudhry V, Feldman EL, Griffin JW, Cornblath DR, Denys EH, Glasberg M, Kuncl RW, Olney RK, Yee WC. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Ann Neurol. 1990 Mar;27(3):316–326. [PubMed]
  • Pestronk A, Adams RN, Kuncl RW, Drachman DB, Clawson LL, Cornblath DR. Differential effects of prednisone and cyclophosphamide on autoantibodies in human neuromuscular disorders. Neurology. 1989 May;39(5):628–633. [PubMed]
  • Nobile-Orazio E, Baldini L, Barbieri S, Marmiroli P, Spagnol G, Francomano E, Scarlato G. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol. 1988 Jul;24(1):93–97. [PubMed]
  • Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989 Aug;46(8):878–884. [PubMed]
  • Trojaborg W, Galassi G, Hays AP, Lovelace RE, Alkaitis M, Latov N. Electrophysiologic study of experimental demyelination induced by serum of patients with IgM M proteins and neuropathy. Neurology. 1989 Dec;39(12):1581–1586. [PubMed]
  • Drachman DB, de Silva S, Ramsay D, Pestronk A. Humoral pathogenesis of myasthenia gravis. Ann N Y Acad Sci. 1987;505:90–105. [PubMed]
  • Sanders DB. The electrodiagnosis of myasthenia gravis. Ann N Y Acad Sci. 1987;505:539–556. [PubMed]
  • Rowland LP. Therapy in myasthenia gravis: introduction. Ann N Y Acad Sci. 1987;505:566–567. [PubMed]
  • Vincent A, Lang B, Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 1989 Dec;12(12):496–502. [PubMed]
  • Newsom-Davis J, Willcox N, Schluep M, Harcourt G, Vincent A, Mossman S, Wray D, Burges J. Immunological heterogeneity and cellular mechanisms in myasthenia gravis. Ann N Y Acad Sci. 1987;505:12–26. [PubMed]
  • Keesey J, Naiem F, Lindstrom J, Roe D, Herrmann C, Jr, Walford R. Acetylcholine receptor antibody titer and HLA-B8 antigen in myasthenia gravis. Arch Neurol. 1982 Feb;39(2):73–77. [PubMed]
  • Dwyer DS, Vakil M, Bradley RJ, Oh SJ, Kearney JF. A possible cause of myasthenia gravis: idiotypic networks involving bacterial antigens. Ann N Y Acad Sci. 1987;505:461–471. [PubMed]
  • Krah DL, Choppin PW. Mice immunized with measles virus develop antibodies to a cell surface receptor for binding virus. J Virol. 1988 May;62(5):1565–1572. [PubMed]
  • Bartholomaeus WN, O'Donoghue H, Foti D, Lawson CM, Shellam GR, Reed WD. Multiple autoantibodies following cytomegalovirus infection: virus distribution and specificity of autoantibodies. Immunology. 1988 Jul;64(3):397–405. [PubMed]
  • Ravindranath RM, Graves MC. Attenuated murine cytomegalovirus binds to N-acetylglucosamine, and shift to virulence may involve recognition of sialic acids. J Virol. 1990 Nov;64(11):5430–5440. [PubMed]
  • Mulder DG, Graves M, Herrmann C. Thymectomy for myasthenia gravis: recent observations and comparisons with past experience. Ann Thorac Surg. 1989 Oct;48(4):551–555. [PubMed]
  • Mulder DG, Herrmann C, Jr, Keesey J, Edwards H. Thymectomy for myasthenia gravis. Am J Surg. 1983 Jul;146(1):61–66. [PubMed]
  • Genkins G, Kornfeld P, Papatestas AE, Bender AN, Matta RJ. Clinical experience in more than 2000 patients with myasthenia gravis. Ann N Y Acad Sci. 1987;505:500–513. [PubMed]
  • Papatestas AE, Genkins G, Kornfeld P, Eisenkraft JB, Fagerstrom RP, Pozner J, Aufses AH., Jr Effects of thymectomy in myasthenia gravis. Ann Surg. 1987 Jul;206(1):79–88. [PubMed]
  • Jaretzki A, 3rd, Penn AS, Younger DS, Wolff M, Olarte MR, Lovelace RE, Rowland LP. "Maximal" thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg. 1988 May;95(5):747–757. [PubMed]
Articles from The Western Journal of Medicine are provided here courtesy of
BMJ Group

PubMed articles by these authors